<p><strong>金医疗国际有限公司</strong>（NASDAQ:ZJYL）的股价在过去一个月表现非常糟糕，下降了 33%。最近的下跌使得过去一年对股东来说是灾难性的，他们在此期间的损失达到了 83%。</p>
<p>即使在如此大幅的价格下跌之后，金医疗国际目前可能仍在发出非常悲观的信号，其市盈率（&#34;P/E&#34;）为 38 倍，因为美国几乎一半的公司市盈率低于 18 倍，甚至低于 11 倍的市盈率也并不罕见。不过，仅仅根据市盈率来判断并不明智，因为可能有解释说明其如此高的原因。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p>例如，考虑到金医疗国际最近的财务表现不佳，其收益一直在下降。许多人可能仍然期望该公司在未来一段时间内表现优于大多数其他公司，这使得市盈率没有崩溃。你真的希望如此，否则你将为没有特别理由的高价格买单。</p>
<p>查看我们对金医疗国际的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1760091693748?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1760091693748"/></p>
<p>NasdaqCM:ZJYL 市盈率与行业比较 2025 年 10 月 10 日</p>
<p>虽然没有关于金医疗国际的分析师预测，但请查看这个 <strong>免费的</strong> 数据丰富的可视化，看看该公司在收益、收入和现金流方面的表现。</p>
<h2>金医疗国际的增长趋势如何？</h2>
<p>金医疗国际的市盈率对于一家预计将实现强劲增长的公司来说是典型的，重要的是，它的表现将远超市场。</p>
<p>回顾过去一年，该公司的净利润下降了 39%。过去三年的表现也不佳，因为该公司的每股收益总共下降了 99%。因此，股东们对中期收益增长率感到沮丧。</p>
<p>将这一中期收益轨迹与市场对未来一年 15% 的扩张预测进行比较，显示出这并不乐观。</p>
<p>根据这些信息，我们发现金医疗国际的市盈率高于市场，这令人担忧。显然，许多投资者对该公司的看法比近期的表现要乐观得多，并且不愿意以任何价格出售他们的股票。如果市盈率降至与近期负增长率更为一致的水平，现有股东很可能会面临未来的失望。</p>
<h2>关键要点</h2>
<p>金医疗国际的股票可能已经回落，但其市盈率仍然高企。我们认为市盈率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
<p>我们对金医疗国际的审查显示，其中期收益的下降并没有像我们预测的那样对其高市盈率产生太大影响，因为市场预计将增长。当我们看到收益下滑并且表现不及市场预期时，我们怀疑股价面临下跌风险，从而使高市盈率降低。如果近期中期收益趋势持续下去，将使股东的投资面临重大风险，并使潜在投资者面临支付过高溢价的危险。</p>
<p>还有其他重要的风险因素需要考虑，我们发现 <strong>金医疗国际的 4 个警告信号</strong>（其中 1 个让我们感到不安！）在投资前你应该了解。</p>
<p>当然，<strong>你可能会通过寻找一些优秀的候选者找到一个绝佳的投资机会。</strong> 所以请查看这个 <strong>免费的</strong> 强劲增长记录的公司名单，它们的市盈率较低。</p>

中进医疗

<p>中进医疗国际有限公司（NASDAQ:ZJYL）的股价在过去一个月内暴跌了 33%，导致股东在过去一年中损失了 83%。尽管出现这种下滑，该公司的市盈率仍高达 38 倍，显示出投资者的乐观情绪。然而，随着收益下降 39% 以及每股收益在三年内下降 99%，人们对这种估值的可持续性产生了担忧。分析师警告称，如果收益继续下降，股价可能会进一步下跌，这对当前和潜在的投资者构成风险</p>

<p>The <strong>Jin Medical International Ltd.</strong> (NASDAQ:ZJYL) share price has fared very poorly over the last month, falling by a substantial 33%. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 83% loss during that time.</p>
<div class="lb-trans"><p><strong>金医疗国际有限公司</strong>（NASDAQ:ZJYL）的股价在过去一个月表现非常糟糕，下降了 33%。最近的下跌使得过去一年对股东来说是灾难性的，他们在此期间的损失达到了 83%。</p>
</div><p>Even after such a large drop in price, Jin Medical International may still be sending very bearish signals at the moment with a price-to-earnings (or &#34;P/E&#34;) ratio of 38x, since almost half of all companies in the United States have P/E ratios under 18x and even P/E's lower than 11x are not unusual. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.</p>
<div class="lb-trans"><p>即使在如此大幅的价格下跌之后，金医疗国际目前可能仍在发出非常悲观的信号，其市盈率（&#34;P/E&#34;）为 38 倍，因为美国几乎一半的公司市盈率低于 18 倍，甚至低于 11 倍的市盈率也并不罕见。不过，仅仅根据市盈率来判断并不明智，因为可能有解释说明其如此高的原因。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p>For example, consider that Jin Medical International's financial performance has been poor lately as its earnings have been in decline. It might be that many expect the company to still outplay most other companies over the coming period, which has kept the P/E from collapsing. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.</p>
<div class="lb-trans"><p>例如，考虑到金医疗国际最近的财务表现不佳，其收益一直在下降。许多人可能仍然期望该公司在未来一段时间内表现优于大多数其他公司，这使得市盈率没有崩溃。你真的希望如此，否则你将为没有特别理由的高价格买单。</p>
</div><p>See our latest analysis for Jin Medical International</p>
<div class="lb-trans"><p>查看我们对金医疗国际的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1760091693748" alt="" original-src="https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1760091693748"/></p>
<p>NasdaqCM:ZJYL Price to Earnings Ratio vs Industry October 10th 2025</p>
<div class="lb-trans"><p>NasdaqCM:ZJYL 市盈率与行业比较 2025 年 10 月 10 日</p>
</div><p>Although there are no analyst estimates available for Jin Medical International, take a look at this <strong>free</strong> data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.</p>
<div class="lb-trans"><p>虽然没有关于金医疗国际的分析师预测，但请查看这个 <strong>免费的</strong> 数据丰富的可视化，看看该公司在收益、收入和现金流方面的表现。</p>
</div><h2>How Is Jin Medical International's Growth Trending?</h2>
<div class="lb-trans"><h2>金医疗国际的增长趋势如何？</h2>
</div><p>Jin Medical International's P/E ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the market.</p>
<div class="lb-trans"><p>金医疗国际的市盈率对于一家预计将实现强劲增长的公司来说是典型的，重要的是，它的表现将远超市场。</p>
</div><p>Retrospectively, the last year delivered a frustrating 39% decrease to the company's bottom line. The last three years don't look nice either as the company has shrunk EPS by 99% in aggregate. Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.</p>
<div class="lb-trans"><p>回顾过去一年，该公司的净利润下降了 39%。过去三年的表现也不佳，因为该公司的每股收益总共下降了 99%。因此，股东们对中期收益增长率感到沮丧。</p>
</div><p>Weighing that medium-term earnings trajectory against the broader market's one-year forecast for expansion of 15% shows it's an unpleasant look.</p>
<div class="lb-trans"><p>将这一中期收益轨迹与市场对未来一年 15% 的扩张预测进行比较，显示出这并不乐观。</p>
</div><p>With this information, we find it concerning that Jin Medical International is trading at a P/E higher than the market. Apparently many investors in the company are way more bullish than recent times would indicate and aren't willing to let go of their stock at any price. There's a very good chance existing shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with the recent negative growth rates.</p>
<div class="lb-trans"><p>根据这些信息，我们发现金医疗国际的市盈率高于市场，这令人担忧。显然，许多投资者对该公司的看法比近期的表现要乐观得多，并且不愿意以任何价格出售他们的股票。如果市盈率降至与近期负增长率更为一致的水平，现有股东很可能会面临未来的失望。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><p>Jin Medical International's shares may have retreated, but its P/E is still flying high. We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>金医疗国际的股票可能已经回落，但其市盈率仍然高企。我们认为市盈率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
</div><p>Our examination of Jin Medical International revealed its shrinking earnings over the medium-term aren't impacting its high P/E anywhere near as much as we would have predicted, given the market is set to grow. When we see earnings heading backwards and underperforming the market forecasts, we suspect the share price is at risk of declining, sending the high P/E lower. If recent medium-term earnings trends continue, it will place shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.</p>
<div class="lb-trans"><p>我们对金医疗国际的审查显示，其中期收益的下降并没有像我们预测的那样对其高市盈率产生太大影响，因为市场预计将增长。当我们看到收益下滑并且表现不及市场预期时，我们怀疑股价面临下跌风险，从而使高市盈率降低。如果近期中期收益趋势持续下去，将使股东的投资面临重大风险，并使潜在投资者面临支付过高溢价的危险。</p>
</div><p>There are also other vital risk factors to consider and we've discovered <strong>4 warning signs for Jin Medical International</strong> (1 doesn't sit too well with us!) that you should be aware of before investing here.</p>
<div class="lb-trans"><p>还有其他重要的风险因素需要考虑，我们发现 <strong>金医疗国际的 4 个警告信号</strong>（其中 1 个让我们感到不安！）在投资前你应该了解。</p>
</div><p>Of course, <strong>you might find a fantastic investment by looking at a few good candidates.</strong> So take a peek at this <strong>free</strong> list of companies with a strong growth track record, trading on a low P/E.</p>
<div class="lb-trans"><p>当然，<strong>你可能会通过寻找一些优秀的候选者找到一个绝佳的投资机会。</strong> 所以请查看这个 <strong>免费的</strong> 强劲增长记录的公司名单，它们的市盈率较低。</p>
</div>

由于中进医疗国际有限公司（NASDAQ:ZJYL）的股价下跌了 33%，一些股东正在寻求退出